onartuzumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458283791

| type = mab

| image =

| alt =

| mab_type = Fab

| source = zu/o

| target = scatter factor receptor kinase

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1133766-06-9

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = MS1J9720WC

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=4422 | H=6820 | N=1168 | O=1363 | S=31

}}

Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}{{cite journal |vauthors=Padda S, Neal JW, Wakelee HA |title=MET inhibitors in combination with other therapies in non-small cell lung cancer |journal=Transl Lung Cancer Res |volume=1 |issue=4 |pages=238–53 |date=December 2012 |pmid=25806189 |pmc=4367550 |doi=10.3978/j.issn.2218-6751.2012.10.08 }}{{cite journal |vauthors=Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F |title=Onartuzumab in lung cancer: the fall of Icarus? |journal=Expert Rev Anticancer Ther |volume=15 |issue=5 |pages=487–9 |date=May 2015 |pmid=25818471 |doi=10.1586/14737140.2015.1031219 |doi-access=free }}

Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials.{{cite journal |vauthors=Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S |title=Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors |journal=J Clin Pharmacol |volume=53 |issue=11 |pages=1103–11 |date=November 2013 |pmid=23922054 |doi=10.1002/jcph.148 |s2cid=206059437 }}{{cite journal |vauthors=Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H |title=Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer |journal=Clin Lung Cancer |volume=13 |issue=6 |pages=500–4 |date=November 2012 |pmid=23063071 |doi=10.1016/j.cllc.2012.05.009 }}{{cite journal |vauthors=Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC |title=Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer |journal=J. Clin. Oncol. |volume=31 |issue=32 |pages=4105–14 |date=November 2013 |pmid=24101053 |pmc=4878106 |doi=10.1200/JCO.2012.47.4189 }}{{cite journal |vauthors=Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T |title=Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer |journal=Invest New Drugs |volume=33 |issue=3 |pages=632–40 |date=June 2015 |pmid=25777467 |doi=10.1007/s10637-015-0227-5 |s2cid=20118425 }}